TSH Biopharm Corp Ltd is a Taiwan-based company mainly engaged in the manufacture and sales of medications. The Company mainly provides cardiovascular medications, gastrointestinal medication, central nervous system medications, and precision medical testing, including Amtrel, Rhynorm, Mopride, Aleviatin, Lonine, and others. The Company also provides vaccine, health supplement and testing services. Sales channels include hospitals and open clinics. The Company mainly distributes its products in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-21	NT$50.50	-0.20%	21,134
26-09-18	NT$50.60	+1.00%	36,152
26-09-17	NT$50.10	0.00%	18,031
26-09-16	NT$50.10	+0.40%	9,020
26-09-15	NT$49.90	-0.60%	7,162

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-09-21			5-day change	1st Jan Change
50.50 ^TWD	-0.20%		+0.60%	-13.68%

08-04	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1.94B 61.07M 53.25M 50.15M 45.67M 85.63M 5.85B 85.73M 601M 231M 2.98B 229M 224M 9.62B	P/E 2024	20.9x	P/E 2025	16.2x
Enterprise Value	1.03B 32.3M 28.16M 26.52M 24.15M 45.28M 3.09B 45.34M 318M 122M 1.58B 121M 119M 5.09B	EV / Sales 2024	1.32x	EV / Sales 2025	1x
Free-Float	34.36%	Yield 2024	3.46%	Yield 2025	4.46%

08-04	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-04	TSH Biopharm Corporation Limited announces Annual dividend, payable on July 13, 2026	CI
12-08	Zhaoke Ophthalmology Limited Enters into Strategic Partnership with TSH Biopharm Corporation Limited	CI
11-05	TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-03	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-07	TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-02-23	TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-20	TSH Biopharm Corporation Limited announces Annual dividend, payable on July 11, 2025	CI
24-11-24	TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-12	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-07	TSH Biopharm Corporation Limited Appoints Remuneration Committee	CI

22-08-09	TSH Biopharm : is invited to attend the online institutional investor conference hosted by IBF Securities	PU
22-08-04	TSH Biopharm : Board of Directors Approved Financial Statements For the Six Months Ended June 30, 2022	PU
22-08-04	TSH Biopharm : Announcement of setting up the Sustainable Development Committee and members of TSH's first Sustainable Development Committee	PU
22-05-24	TSH Biopharm : was invited to attend the online institutional investor conference hosted by Concord Securities	PU
22-05-24	TSH Biopharm : Announcement of Change to Remuneration Committee member	PU

TSH Biopharm Corporation Limited Stock

Stocks

8432

TW0008432006

Pharmaceuticals

Valuation: TSH Biopharm Corporation Limited

Chart: TSH Biopharm Corporation Limited

Latest news: TSH Biopharm Corporation Limited

Press Releases: TSH Biopharm Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: TSH Biopharm Corporation Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.20%
1 week	+0.60%
Current month	+0.20%
3 months	-1.37%
6 months	-1.94%
Current year	-13.68%

1 week	49.85	50.9
1 month	49.7	51.4
Current year	48.6	58.9
1 year	48.6	59.3
3 years	43	71.1
5 years	39	71.1
10 years	38.8	101.5

Manager	Title	Age	Since
Ssu Yuan Yang CEO	Chief Executive Officer	-	2019-01-16
Chen Ju Kan DFI	Director of Finance/CFO	-	2010-08-31
Shu Ping Huang ADM	Chief Administrative Officer	-	-

Director	Title	Age	Since
Kun Hung Lai BRD	Director/Board Member	-	2011-10-05
Chao I Chiang BRD	Director/Board Member	-	2016-06-22
Zhi Li Wang BRD	Director/Board Member	-	2017-06-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TSH BIOPHARM CORPORATION LIMITED	-0.20%	+0.60%	-3.44%	+10.62%	61.07M
ELI LILLY AND COMPANY	+1.04%	+2.34%	+54.91%	+111.75%	1,038B
JOHNSON & JOHNSON	-0.19%	+1.18%	+52.94%	+66.69%	649B
ABBVIE INC.	+0.20%	+1.04%	+18.88%	+72.38%	467B
ROCHE HOLDING AG	+2.24%	+0.94%	+37.61%	+45.31%	355B
NOVARTIS AG	+0.90%	+1.95%	+18.79%	+25.27%	269B
ASTRAZENECA PLC	+0.48%	+3.34%	+11.11%	+15.38%	260B
AMGEN INC.	+1.95%	+3.06%	+37.75%	+45.93%	213B
NOVO NORDISK A/S	-7.65%	-7.28%	-33.09%	-59.52%	176B
GILEAD SCIENCES, INC.	+0.30%	+2.83%	+31.97%	+100.03%	187B
Average	-0.00%	+1.06%	+22.74%	+43.38%	361.52B
Weighted average by Cap.	+0.60%	+1.47%	+35.87%	+65.83%

	2024	2025
Net sales	1.12B 35.14M 30.64M 28.85M 26.28M 49.27M 3.37B 49.33M 346M 133M 1.71B 132M 129M 5.53B	1.34B 42.09M 36.7M 34.56M 31.48M 59.02M 4.03B 59.09M 414M 160M 2.05B 158M 155M 6.63B
Net income	113M 3.56M 3.11M 2.92M 2.66M 4.99M 341M 5M 35.03M 13.5M 174M 13.38M 13.08M 561M	139M 4.39M 3.82M 3.6M 3.28M 6.15M 420M 6.16M 43.13M 16.62M 214M 16.47M 16.11M 691M
Net Debt	-877M -27.62M -24.08M -22.68M -20.65M -38.72M -2.65B -38.77M -272M -105M -1.35B -104M -101M -4.35B	-914M -28.77M -25.09M -23.63M -21.52M -40.34M -2.76B -40.39M -283M -109M -1.4B -108M -106M -4.53B